Diabetes and Retinal Vascular Dysfunction

Journal of Ophthalmic and Vision Research

Volumn 9, Issue 3, 2014, Pages 362-373

  Shin, Eui Seok ^a   Sorenson, Christine M ^a   Sheibani, Nader ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Diabetes; Inflammation; Oxidative Stress; Retinal vasculature; Thrombospondins

Indexed keywords

EID: 84930945677     PISSN: 20082010     EISSN: 2008322X     Source Type: Journal    
DOI: 10.4103/2008-322X.143378     Document Type: Review

References (135)

1. Runkle EA, Antonetti DA. The blood-retinal barrier: Structure and functional significance. Methods Mol Biol 2011;686:133-148.
2. Kaur C, Foulds WS, Ling EA. Blood-retinal barrier in hypoxic ischaemic conditions: Basic concepts, clinical features and management. Prog Retin Eye Res 2008;27:622-647.
3. Hosoya K, Tachikawa M. Inner blood-retinal barrier transporters: Role of retinal drug delivery. Pharm Res 2009;26:2055-2065.
4. Klaassen I, Van Noorden CJ, Schlingemann RO. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog Retin Eye Res 2013;34:19-48.
5. Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner TW, Jefferson LS, et al. Diabetic retinopathy: Seeing beyond glucose-induced microvascular disease. Diabetes 2006;55:2401-2411.
6. Guariguata L. By the numbers: new estimates from the IDF Diabetes Atlas Update for 2012. Diabetes Res Clin Pract. 2012;98:524-525.
7. Kempen JH, O'Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004;122:552-563.
8. Roy MS, Klein R, O'Colmain BJ, Klein BE, Moss SE, Kempen JH. The prevalence of diabetic retinopathy among adult type 1 diabetic persons in the United States. Arch Ophthalmol 2004;122:546-551.
9. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556-564.
10. Bandello F, Lattanzio R, Zucchiatti I, Del Turco C. Pathophysiology and treatment of diabetic retinopathy. Acta Diabetol 2013;50:1-20.
11. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 2009;54:1-32.
12. Bandello F, Lattanzio R, Zucchiatti I, Del Turco C. Pathophysiology and treatment of diabetic retinopathy. Acta Diabetol 2013;50:1-20.
13. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: A review. Diabetologia 2001;44:129-146.
14. Lecomte M, Denis U, Ruggiero D, Lagarde M, Wiernsperger N. Involvement of caspase-10 in advanced glycation endproduct-induced apoptosis of bovine retinal pericytes in culture. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2004;1689(3):202-11.
15. Yamagishi S, Takeuchi M, Matsui T, Nakamura K, Imaizumi T, Inoue H. Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression. FEBS Lett 2005;579:4265-4270.
16. Kim JH, Kim JH, Jun HO, Yu YS, Kim KW. Inhibition of protein kinase C delta attenuates blood-retinal barrier breakdown in diabetic retinopathy. Am J Pathol 2010;176:1517-1524.
17. Gardiner TA, Anderson HR, Stitt AW. Inhibition of advanced glycation end-products protects against retinal capillary basement membrane expansion during long-term diabetes. J Pathol 2003;201:328-333.
18. Stitt AW, Hughes SJ, Canning P, Lynch O, Cox O, Frizzell N, et al. Substrates modified by advanced glycation end-products cause dysfunction and death in retinal pericytes by reducing survival signals mediated by platelet-derived growth factor. Diabetologia 2004;47:1735-1746.
19. Kowluru RA, Chan PS. Oxidative stress and diabetic retinopathy. Exp Diabetes Res 2007;2007:43603.
20. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991;40:405-412.
21. Li J, Wang JJ, Yu Q, Chen K, Mahadev K, Zhang SX. Inhibition of reactive oxygen species by Lovastatin downregulates vascular endothelial growth factor expression and ameliorates blood-retinal barrier breakdown in db/db mice: Role of NADPH oxidase 4. Diabetes 2010;59:1528-1538.
22. Zheng Z, Chen H, Ke G, Fan Y, Zou H, Sun X, et al. Protective effect of perindopril on diabetic retinopathy is associated with decreased vascular endothelial growth factor-to-pigment epithelium-derived factor ratio: involvement of a mitochondria-reactive oxygen species pathway. Diabetes 2009;58:954-964.
23. Al-Shabrawey M, Rojas M, Sanders T, Behzadian A, El-Remessy A, Bartoli M, et al. Role of NADPH oxidase in retinal vascular inflammation. Invest Ophthalmol Vis Sci 2008;49:3239-3244.
24. Warboys CM, Toh HB, Fraser PA. Role of NADPH oxidase in retinal microvascular permeability increase by RAGE activation. Invest Ophthalmol Vis Sci 2009;50:1319-1328.
25. Pricci F, Leto G, Amadio L, Iacobini C, Cordone S, Catalano S, et al. Oxidative stress in diabetes-induced endothelial dysfunction involvement of nitric oxide and protein kinase C. Free Radic Biol Med 2003;35:683-694.
26. Zheng Z, Chen H, Li J, Li T, Zheng B, Zheng Y, et al. Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin. Diabetes 2012;61:217-228.
27. Du Y, Veenstra A, Palczewski K, Kern TS. Photoreceptor cells are major contributors to diabetes-induced oxidative stress and local inflammation in the retina. Proc Natl Acad Sci USA 2013;110:16586-16591.
28. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res 2011;30:343-358.
29. Zheng L, Du Y, Miller C, Gubitosi-Klug RA, Ball S, Berkowitz BA, et al. Critical role of inducible nitric oxide synthase in degeneration of retinal capillaries in mice with streptozotocin-induced diabetes. Diabetologia 2007;50:1987-1996.
30. Mishra A, Newman EA. Inhibition of inducible nitric oxide synthase reverses the loss of functional hyperemia in diabetic retinopathy. Glia 2010;58:1996-2004.
31. Mishra A, Newman EA. Aminoguanidine reverses the loss of functional hyperemia in a rat model of diabetic retinopathy. Front Neuroenergetics 2011;3:10.
32. Perrone L, Devi TS, Hosoya KI, Terasaki T, Singh LP. Inhibition of TXNIP expression in vivo blocks early pathologies of diabetic retinopathy. Cell Death Dis 2010;1:e65.
33. Ayalasomayajula SP, Kompella UB. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur J Pharmacol 2005;511:191-198.
34. Talahalli R, Zarini S, Tang J, Li G, Murphy R, Kern TS, et al. Leukocytes regulate retinal capillary degeneration in the diabetic mouse via generation of leukotrienes. J Leukoc Biol 2013;93:135-143.
35. Krady JK, Basu A, Allen CM, Xu Y, LaNoue KF, Gardner TW, et al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes 2005;54:1559-1565.
36. Li J, Wang JJ, Yu Q, Wang M, Zhang SX. Endoplasmic reticulum stress is implicated in retinal inflammation and diabetic retinopathy. FEBS Lett 2009;583:1521-1527.
37. Yang W, Yu X, Zhang Q, Lu Q, Wang J, Cui W, et al. Attenuation of streptozotocin-induced diabetic retinopathy with low molecular weight fucoidan via inhibition of vascular endothelial growth factor. Exp Eye Res 2013;115:96-105.
38. Hu Y, Chen Y, Ding L, He X, Takahashi Y, Gao Y, et al. Pathogenic role of diabetes-induced PPAR-a down-regulation in microvascular dysfunction. Proc Natl Acad Sci USA 2013;110:15401-15406.
39. Liu X, Chen HH, Zhang LW. Potential therapeutic effects of pigment epithelium-derived factor for treatment of diabetic retinopathy. Int J Ophthalmol 2013;6:221-227.
40. Yoshida Y, Yamagishi S, Matsui T, Jinnouchi Y, Fukami K, Imaizumi T, et al. Protective role of pigment epithelium-derived factor (PEDF) in early phase of experimental diabetic retinopathy. Diabetes Metab Res Rev 2009;25:678-686.
41. Park K, Lee K, Zhang B, Zhou T, He X, Gao G, et al. Identification of a Novel Inhibitor of the Canonical Wnt Pathway. Mol Cell Biol. 2011 July 15, 2011;31(14):3038-51.
42. Sheibani N, Sorenson CM, Cornelius LA, Frazier WA. Thrombospondin-1, a natural inhibitor of angiogenesis, is present in vitreous and aqueous humor and is modulated by hyperglycemia. Biochem Biophys Res Commun 2000;267:257-261.
43. Wang S, Gottlieb JL, Sorenson CM, Sheibani N. Modulation of thrombospondin 1 and pigment epithelium-derived factor levels in vitreous fluid of patients with diabetes. Arch Ophthalmol 2009;127:507-513.
44. Sorenson CM, Wang S, Gendron R, Paradis H, Sheibani N. Thrombospondin-1 deficiency exacerbates the pathogenesis of diabetic retinopathy. J Diabetes Metab 2013;Suppl 12:005. doi:10. 4172/2155-6156. S12-005
45. Han Y, Bearse MA Jr, Schneck ME, Barez S, Jacobsen CH, Adams AJ. Multifocal electroretinogram delays predict sites of subsequent diabetic retinopathy. Invest Ophthalmol Vis Sci 2004;45:948-954.
46. Barber AJ, Gardner TW, Abcouwer SF. The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy. Invest Ophthalmol Vis Sci 2011;52:1156-1163.
47. El-Remessy AB, Al-Shabrawey M, Khalifa Y, Tsai NT, Caldwell RB, Liou GI. Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol 2006;168:235-244.
48. Kowluru RA, Engerman RL, Case GL, Kern TS. Retinal glutamate in diabetes and effect of antioxidants. Neurochem Int 2001;38:385-390.
49. Davalli AM, Perego C, Folli FB. The potential role of glutamate in the current diabetes epidemic. Acta Diabetol 2012;49:167-183.
50. Ng JS, Bearse MA Jr, Schneck ME, Barez S, Adams AJ. Local diabetic retinopathy prediction by multifocal ERG delays over 3 years. Invest Ophthalmol Vis Sci 2008;49:1622-1628.
51. Ngoh GA, Facundo HT, Zafir A, Jones SP. O-GlcNAc signaling in the cardiovascular system. Circ Res 2010;107:171-185.
52. Gurel Z, Sieg KM, Shallow KD, Sorenson CM, Sheibani N. Retinal O-linked N-acetylglucosamine protein modifications: Implications for postnatal retinal vascularization and the pathogenesis of diabetic retinopathy. Mol Vis 2013;19:1047-1059.
53. Kadiyala CS, Zheng L, Du Y, Yohannes E, Kao HY, Miyagi M, et al. Acetylation of retinal histones in diabetes increases inflammatory proteins: Effects of minocycline and manipulation of histone acetyltransferase (HAT) and histone deacetylase (HDAC). J Biol Chem 2012;287:25869-25880.
54. D'Cruz TS, Weibley BN, Kimball SR, Barber AJ. Post-translational processing of synaptophysin in the rat retina is disrupted by diabetes. PLoS One 2012;7:e44711.
55. Kim YH, Kim YS, Roh GS, Choi WS, Cho GJ. Resveratrol blocks diabetes-induced early vascular lesions and vascular endothelial growth factor induction in mouse retinas. Acta Ophthalmol 2012;90:e31-e37.
56. Murakami T, Frey T, Lin C, Antonetti DA. Protein kinase cß phosphorylates occludin regulating tight junction trafficking in vascular endothelial growth factor-induced permeability in vivo. Diabetes 2012;61:1573-1583.
57. Mizutani M, Kern TS, Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest 1996;97:2883-2890.
58. Barber AJ, Antonetti DA, Kern TS, Reiter CE, Soans RS, Krady JK, et al. The Ins2Akita mouse as a model of early retinal complications in diabetes. Invest Ophthalmol Vis Sci 2005;46:2210-2218.
59. Enge M, Bjarnegård M, Gerhardt H, Gustafsson E, Kalén M, Asker N, et al. Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy. EMBO J 2002;21:4307-4316.
60. Engerman RL. Pathogenesis of diabetic retinopathy. Diabetes 1989;38:1203-1206.
61. Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont AC, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA 1999;96:10836-10841.
62. Bai N, Tang S, Ma J, Luo Y, Lin S. Increased expression of intercellular adhesion molecule-1, vascular cellular adhesion molecule-1 and leukocyte common antigen in diabetic rat retina. Yan Ke Xue Bao 2003;19:176-183.
63. Costa PZ, Soares R. Neovascularization in diabetes and its complications. Unraveling the angiogenic paradox. Life Sci 2013;92:1037-1045.
64. Villeneuve LM, Natarajan R. The role of epigenetics in the pathology of diabetic complications. Am J Physiol Renal Physiol 2010;299:F14-F25.
65. Chen S, Feng B, George B, Chakrabarti R, Chen M, Chakrabarti S. Transcriptional coactivator p300 regulates glucose-induced gene expression in endothelial cells. Am J Physiol Endocrinol Metab 2010;298:E127-E137.
66. Zhong Q, Kowluru RA. Role of histone acetylation in the development of diabetic retinopathy and the metabolic memory phenomenon. J Cell Biochem 2010;110:1306-1313.
67. Zhong Q, Kowluru RA. Regulation of matrix metalloproteinase-9 by epigenetic modifications and the development of diabetic retinopathy. Diabetes 2013;62:2559-2568.
68. He S, Li X, Chan N, Hinton DR. Review: Epigenetic mechanisms in ocular disease. Mol Vis 2013;19:665-674.
69. McArthur K, Feng B, Wu Y, Chen S, Chakrabarti S. MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. Diabetes 2011;60:1314-1323.
70. Murray AR, Chen Q, Takahashi Y, Zhou KK, Park K, Ma JX. MicroRNA-200b downregulates oxidation resistance 1 (Oxr1) expression in the retina of type 1 diabetes model. Invest Ophthalmol Vis Sci 2013;54:1689-1697.
71. Kovacs B, Lumayag S, Cowan C, Xu S. MicroRNAs in early diabetic retinopathy in streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci 2011;52:4402-4409.
72. Ling S, Birnbaum Y, Nanhwan MK, Thomas B, Bajaj M, Ye Y. MicroRNA-dependent cross-talk between VEGF and HIF1a in the diabetic retina. Cell Signal 2013;25:2840-2847.
73. Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW. Diabetic retinopathy: More than meets the eye. Surv Ophthalmol 2002;47 Suppl 2:S253-S262.
74. Abbott NJ, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006;7:41-53.
75. Armulik A, Genové G, Mäe M, Nisancioglu MH, Wallgard E, Niaudet C, et al. Pericytes regulate the blood-brain barrier. Nature 2010;468:557-561.
76. Al Ahmad A, Gassmann M, Ogunshola OO. Maintaining blood-brain barrier integrity: Pericytes perform better than astrocytes during prolonged oxygen deprivation. J Cell Physiol 2009;218:612-622.
77. Dejana E. Endothelial cell-cell junctions: Happy together. Nat Rev Mol Cell Biol 2004;5:261-270.
78. Vestweber D. VE-cadherin: the major endothelial adhesion molecule controlling cellular junctions and blood vessel formation. Arterioscler Thromb Vasc Biol 2008;28:223-232.
79. Taddei A, Giampietro C, Conti A, Orsenigo F, Breviario F, Pirazzoli V, et al. Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5. Nat Cell Biol 2008;10:923-934.
80. González-Mariscal L, Betanzos A, Nava P, Jaramillo BE. Tight junction proteins. Prog Biophys Mol Biol 2003;81:1-44.
81. Wolburg H, Noell S, Mack A, Wolburg-Buchholz K, Fallier-Becker P. Brain endothelial cells and the glio-vascular complex. Cell Tissue Res 2009;335:75-96.
82. Sawada N, Murata M, Kikuchi K, Osanai M, Tobioka H, Kojima T, et al. Tight junctions and human diseases. Med Electron Microsc 2003;36:147-156.
83. Dejana E, Giampietro C. Vascular endothelial-cadherin and vascular stability. Curr Opin Hematol 2012;19:218-223.
84. Nagasawa K, Chiba H, Fujita H, Kojima T, Saito T, Endo T, et al. Possible involvement of gap junctions in the barrier function of tight junctions of brain and lung endothelial cells. J Cell Physiol 2006;208:123-132.
85. Quaegebeur A, Segura I, Carmeliet P. Pericytes: Blood-brain barrier safeguards against neurodegeneration? Neuron 2010;68:321-323.
86. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res 2005;97:512-523.
87. Bobbie MW, Roy S, Trudeau K, Munger SJ, Simon AM, Roy S. Reduced connexin 43 expression and its effect on the development of vascular lesions in retinas of diabetic mice. Invest Ophthalmol Vis Sci 2010;51:3758-3763.
88. Shepro D, Morel NM. Pericyte physiology. FASEB J 1993;7:1031-1038.
89. Tomasek JJ, Haaksma CJ, Schwartz RJ, Vuong DT, Zhang SX, Ash JD, et al. Deletion of smooth muscle alpha-actin alters blood-retina barrier permeability and retinal function. Invest Ophthalmol Vis Sci 2006;47:2693-2700.
90. Darland DC, Massingham LJ, Smith SR, Piek E, Saint-Geniez M, D'Amore PA. Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev Biol 2003;264:275-288.
91. Simonavicius N, Ashenden M, van Weverwijk A, Lax S, Huso DL, Buckley CD, et al. Pericytes promote selective vessel regression to regulate vascular patterning. Blood 2012;120:1516-1527.
92. Walshe TE, Saint-Geniez M, Maharaj AS, Sekiyama E, Maldonado AE, D'Amore PA. TGF-beta is required for vascular barrier function, endothelial survival and homeostasis of the adult microvasculature. PLoS One 2009;4:e5149.
93. Ejaz S, Chekarova I, Ejaz A, Sohail A, Lim CW. Importance of pericytes and mechanisms of pericyte loss during diabetes retinopathy. Diabetes Obes Metab 2008;10:53-56.
94. Watanabe T, Raff MC. Retinal astrocytes are immigrants from the optic nerve. Nature 1988;332:834-837.
95. Schnitzer J. Retinal astrocytes: Their restriction to vascularized parts of the mammalian retina. Neurosci Lett 1987;78:29-34.
96. Chan-Ling T, Stone J. Degeneration of astrocytes in feline retinopathy of prematurity causes failure of the blood-retinal barrier. Invest Ophthalmol Vis Sci 1992;33:2148-2159.
97. Choi YK, Kim KW. Blood-neural barrier: Its diversity and coordinated cell-to-cell communication. BMB Rep 2008;41:345-352.
98. Gardner TW, Lieth E, Khin SA, Barber AJ, Bonsall DJ, Lesher T, et al. Astrocytes increase barrier properties and ZO-1 expression in retinal vascular endothelial cells. Invest Ophthalmol Vis Sci 1997;38:2423-2427.
99. Choi YK, Kim KW. AKAP12 in astrocytes induces barrier functions in human endothelial cells through protein kinase Czeta. FEBS J 2008;275:2338-2353.
100. Nishikiori N, Osanai M, Chiba H, Kojima T, Mitamura Y, Ohguro H, et al. Glial cell-derived cytokines attenuate the breakdown of vascular integrity in diabetic retinopathy. Diabetes 2007;56:1333-1340.
101. Alvarez JI, Dodelet-Devillers A, Kebir H, Ifergan I, Fabre PJ, Terouz S, et al. The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence. Science 2011;334:1727-1731.
102. Kim JH, Kim JH, Yu YS, Kim DH, Kim KW. Recruitment of pericytes and astrocytes is closely related to the formation of tight junction in developing retinal vessels. J Neurosci Res 2009;87:653-659.
103. Joussen AM, Smyth N, Niessen C. Pathophysiology of diabetic macular edema. Dev Ophthalmol 2007;39:1-12.
104. Cui Y, Xu X, Bi H, Zhu Q, Wu J, Xia X, et al. Expression modification of uncoupling proteins and MnSOD in retinal endothelial cells and pericytes induced by high glucose: The role of reactive oxygen species in diabetic retinopathy. Exp Eye Res 2006;83:807-816.
105. Trudeau K, Molina AJ, Guo W, Roy S. High glucose disrupts mitochondrial morphology in retinal endothelial cells: implications for diabetic retinopathy. Am J Pathol 2010;177:447-455.
106. Du Y, Kowluru A, Kern TS. PP2A contributes to endothelial death in high glucose: Inhibition by benfotiamine. Am J Physiol Regul Integr Comp Physiol 2010;299:R1610-7.
107. Leal EC, Aveleira CA, Castilho AF, Serra AM, Baptista FI, Hosoya K, et al. High glucose and oxidative/nitrosative stress conditions induce apoptosis in retinal endothelial cells by a caspase-independent pathway. Exp Eye Res 2009;88:983-991.
108. Li AF, Roy S. High glucose-induced downregulation of connexin 43 expression promotes apoptosis in microvascular endothelial cells. Invest Ophthalmol Vis Sci 2009;50:1400-1407.
109. Spoerri PE, Afzal A, Li Calzi S, Shaw LC, Cai J, Pan H, et al. Effects of VEGFR-1, VEGFR-2, and IGF-IR hammerhead ribozymes on glucose-mediated tight junction expression in cultured human retinal endothelial cells. Mol Vis 2006;12:32-34.
110. Bhattacharjee PS, Huq TS, Potter V, Young A, Davenport IR, Graves R, et al. High-glucose-induced endothelial cell injury is inhibited by a Peptide derived from human apolipoprotein E. PLoS One 2012;7:e52152.
111. Tien T, Barrette KF, Chronopoulos A, Roy S. Effects of high glucose-induced CX43 downregulation on occludin and ZO-1 expression and tight junction barrier function in retinal endothelial cells. Invest Ophthalmol Vis Sci 2013;54:6518-6525.
112. Huang Q, Sheibani N. High glucose promotes retinal endothelial cell migration through activation of Src, PI3K/Akt1/eNOS, and ERKs. Am J Physiol Cell Physiol 2008;295:C1647-C1657.
113. Chen X, Li J, Li M, Zeng M, Li T, Xiao W, et al. KH902 suppresses high glucose-induced migration and sprouting of human retinal endothelial cells by blocking VEGF and PIGF. Diabetes Obes Metab 2013;15:224-233.
114. Huang Q, Sheibani N. High glucose promotes retinal endothelial cell migration through activation of Src, PI3K/Akt1/eNOS, and ERKs. Am J Physiol Cell Physiol 2008;295:C1647-C1657.
115. Yuan L, Hu J, Luo Y, Liu Q, Li T, Parish CR, et al. Upregulation of heparanase in high-glucose-treated endothelial cells promotes endothelial cell migration and proliferation and correlates with Akt and extracellular-signal-regulated kinase phosphorylation. Mol Vis 2012;18:1684-1695.
116. Su X, Sorenson CM, Sheibani N. Isolation and characterization of murine retinal endothelial cells. Mol Vis 2003;9:171-178.
117. Romeo G, Liu WH, Asnaghi V, Kern TS, Lorenzi M. Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes 2002;51:2241-2248.
118. Takamura Y, Tomomatsu T, Kubo E, Tsuzuki S, Akagi Y. Role of the polyol pathway in high glucose-induced apoptosis of retinal pericytes and proliferation of endothelial cells. Invest Ophthalmol Vis Sci 2008;49:3216-3223.
119. Geraldes P, Hiraoka-Yamamoto J, Matsumoto M, Clermont A, Leitges M, Marette A, et al. Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med 2009;15:1298-1306.
120. Fu D, Wu M, Zhang J, Du M, Yang S, Hammad SM, et al. Mechanisms of modified LDL-induced pericyte loss and retinal injury in diabetic retinopathy. Diabetologia 2012;55:3128-3140.
121. Devi TS, Hosoya K, Terasaki T, Singh LP. Critical role of TXNIP in oxidative stress, DNA damage and retinal pericyte apoptosis under high glucose: Implications for diabetic retinopathy. Exp Cell Res 2013;319:1001-1012.
122. Li Y, Smith D, Li Q, Sheibani N, Huang S, Kern T, et al. Antibody-mediated retinal pericyte injury: Implications for diabetic retinopathy. Invest Ophthalmol Vis Sci 2012;53:5520-5526.
123. Trudeau K, Molina AJ, Roy S. High glucose induces mitochondrial morphology and metabolic changes in retinal pericytes. Invest Ophthalmol Vis Sci 2011;52:8657-8664.
124. Beltramo E, Berrone E, Giunti S, Gruden G, Perin PC, Porta M. Effects of mechanical stress and high glucose on pericyte proliferation, apoptosis and contractile phenotype. Exp Eye Res 2006;83:989-994.
125. Pfister F, Feng Y, vom Hagen F, Hoffmann S, Molema G, Hillebrands JL, et al. Pericyte migration: A novel mechanism of pericyte loss in experimental diabetic retinopathy. Diabetes 2008;57:2495-2502.
126. Tu Z, Li Y, Smith DS, Sheibani N, Huang S, Kern T, et al. Retinal pericytes inhibit activated T cell proliferation. Invest Ophthalmol Vis Sci 2011;52:9005-9010.
127. Shin ES, Huang Q, Gurel Z, Palenski TL, Zaitoun I, Sorenson CM, et al. STAT1-mediated Bim expression promotes the apoptosis of retinal pericytes under high glucose conditions. Cell Death Dis 2014;5:e986.
128. Rungger-Brändle E, Dosso AA, Leuenberger PM. Glial reactivity, an early feature of diabetic retinopathy. Invest Ophthalmol Vis Sci 2000;41:1971-1980.
129. Feit-Leichman RA, Kinouchi R, Takeda M, Fan Z, Mohr S, Kern TS, et al. Vascular damage in a mouse model of diabetic retinopathy: Relation to neuronal and glial changes. Invest Ophthalmol Vis Sci 2005;46:4281-4287.
130. Iandiev I, Pannicke T, Reichenbach A, Wiedemann P, Bringmann A. Diabetes alters the localization of glial aquaporins in rat retina. Neurosci Lett 2007;421:132-136.
131. Ly A, Yee P, Vessey KA, Phipps JA, Jobling AI, Fletcher EL. Early inner retinal astrocyte dysfunction during diabetes and development of hypoxia, retinal stress, and neuronal functional loss. Invest Ophthalmol Vis Sci 2011;52:9316-9326.
132. Lind KR, Ball KK, Cruz NF, Dienel GA. The unfolded protein response to endoplasmic reticulum stress in cultured astrocytes and rat brain during experimental diabetes. Neurochem Int 2013;62:784-795.
133. Xu Z, Wei Y, Gong J, Cho H, Park JK, Sung ER, et al. NRF2 plays a protective role in diabetic retinopathy in mice. Diabetologia 2014;57:204-213.
134. Aghdam SY, Gurel Z, Ghaffarieh A, Sorenson CM, Sheibani N. High glucose and diabetes modulate cellular proteasome function: Implications in the pathogenesis of diabetes complications. Biochem Biophys Res Commun 2013;432:339-344.
135. Gurel Z, Sieg KM, Shallow KD, Sorenson CM, Sheibani N. Retinal O-linked N-acetylglucosamine protein modifications: Implications for postnatal retinal vascularization and the pathogenesis of diabetic retinopathy. Mol Vis 2013;19:1047-1059.